Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Firazyr | icatibant | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Zevalin | Ibritumomab tiuxetan | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| TBD | Entrectinib | Withdrawn | ||||
| Ibrance | Palbociclib | Withdrawn | ||||
| Xeljanz | tofacitinib | Cancelled | ||||
| TBD | Cabozantinib | Withdrawn | ||||
| Ogivri | Trastuzumab | Withdrawn | ||||
| Zytiga | Abiraterone | Withdrawn | ||||
| Admelog | Insulin lispro | Cancelled |
Last Updated : April 16, 2024